FMP
Titan Pharmaceuticals, Inc.
TTNP
NASDAQ
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
6.97 USD
-0.24 (-3.44%)
About
ceo
Mr. David Elliot Lazar
sector
Healthcare
industry
Biotechnology
website
https://www.titanpharm.com
exchange
NASDAQ
Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therape...
CIK
0000910267
ISIN
US8883147055
CUSIP
888314606
Address
400 Oyster Point Boulevard
Phone
650 244 4990
Country
US
Employee
4
IPO Date
Jan 18, 1996
Summary
CIK
0000910267
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
888314606
ISIN
US8883147055
Country
US
Price
6.97
Beta
1.35
Volume Avg.
10.86k
Market Cap
6.37M
Shares
-
52-Week
5.0-16.6
DCF
6.21
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.94
P/B
-
Website
https://www.titanpharm.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TTNP News
It looks like there's no news available.
